Quanterix Corporation

David Wilson

Lei Chang

Linan Song

Dandan Shan

Andreas Jeromin

Carmen Ioana Tobos

Edward Kevin Hrusovsky

Purvish Prahlad Patel

Jeffrey D Randall

Kaj Blennow

John Henrik Zetterberg

Joe C Johnson

Tatiana Plavina

Andrew Ball

Dawn Mattoon

Syrena Fernandes

Jeremy Lambert

The present disclosure relates to immunoassays for NF-L performed on liquid samples derived from physiological fluids such as venous blood to detect the presence or absence of a physiological condition by quantifying one or a combination of NF-L determinations at concentrations indicative of the condition.

Quantification of neurofilament light chain in physiological samples

The present disclosure relates to immunoassays for NF-L, GFAP, UCH L1, and Tau performed on liquid samples derived from physiological fluids such as venous blood to detect the presence or absence of a physiological condition by quantifying one or a combination of NF-L, GFAP, UCH L1, and Tau at concentrations indicative of the condition.

Quantification of biomarkers present in physiological samples

The present disclosure relates to digital immunoassays performed on diluted samples obtained from dried blood spots, for example dried capillary blood samples, to detect the presence or absence of a physiological condition by quantifying one or a combination of biomarkers at concentrations indicative of the condition.

Quantification of biomarkers present in dried physiological samples

The present disclosure relates to methods and compositions, e.g., kits, for quantitatively detecting an antibody of a subject to an infectious organism. In some embodiments, the present disclosure provides for methods and compositions, e.g., kits, for quantitatively detecting a human antibody to SARS-CoV-2 polypeptide or S (spike) polypeptide. Certain applications and uses of the present methods and compositions, e.g., kits, are also provided.

Quantitative antibody test

The present invention, in some embodiments, generally relates to methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury. In some embodiments, the brain injury results from a hypoxic event. In some embodiments, methods are provided for determining a measure of the concentration of tau protein in a patient sample containing or suspected of containing tau protein.

Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury

Growing community of inventors

Boxborough, MA, United States of America

David Wilson